Shortfall in Knowledge of Treatment Optimization for Castration-Resistant Prostate Cancer

Prostate cancer is the tumor type with highest incidence in men in the United States. Typically, the first line treatment for progressive disease is androgen deprivation therapy (ADT). However, most men eventually stop responding to ADT treatment and develop castration-resistant prostate cancer (CRPC). The therapeutic options for this highly heterogeneous disease process have expanded to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metasta...
Continue reading

Androgen Deprivation and Dementia Risk in Prostate Cancer: Tanya Dorff, MD

Androgen deprivation therapy (ADT) is an effective treatment for high-risk prostate cancer in all stages of the disease. However, Ravishankar Jayadevappa, PhD, and colleagues found in a recent population-based study that this commonly used treatment increases diagnoses of dementia and Alzheimer's disease. In this interview with i3 Health, Tanya Dorff, MD, Associate Clinical Professor and Head of the Genitourinary Cancers Program at City of Hope, discusses the study's findings and their potential...
Continue reading

Patients with Prostate Cancer: Is Testosterone Treatment OK?

In this Q&A session at the Oncology Nursing Society (ONS) 44th Annual Congress in Anaheim, California, Kathleen Burns, MSN, ANP, OCN®, addresses whether low-risk patients with prostate cancer can receive testosterone. What are your thoughts on initiating testosterone treatments for men who are low risk, have received some type of treatment, either castration or radiation, but can't handle the low testosterone? Kathleen D. Burns, MSN, ANP, OCN®: We recently completed a clinical trial where we...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.